JAK2 and focal segmental glomerulosclerosis: Authors of this paper hypothesized that albuminuria in FSGS was associated with qualitative or quantitative changes in the CLCF1–CRLF1 complex, and that JAK2 or STAT3 inhibitors might become a novel therapeutic agents to treat FSGS [57].